Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Sees Large Decline in Short Interest

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 5,220,000 shares, a decrease of 31.9% from the October 31st total of 7,670,000 shares. Currently, 2.8% of the company’s shares are short sold. Based on an average daily volume of 37,050,000 shares, the days-to-cover ratio is presently 0.1 days.

Tonix Pharmaceuticals Trading Up 0.7 %

Shares of Tonix Pharmaceuticals stock traded up $0.00 on Friday, hitting $0.19. 28,999,211 shares of the company’s stock traded hands, compared to its average volume of 14,063,675. Tonix Pharmaceuticals has a one year low of $0.12 and a one year high of $22.14. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.33 and a quick ratio of 2.81. The company has a fifty day moving average of $0.16 and a two-hundred day moving average of $1.05. The company has a market capitalization of $35.45 million, a price-to-earnings ratio of 0.00 and a beta of 2.06.

Tonix Pharmaceuticals (NASDAQ:TNXP) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($2.03) by $1.80. The company had revenue of $2.82 million during the quarter, compared to analyst estimates of $2.63 million. Tonix Pharmaceuticals had a negative net margin of 1,197.86% and a negative return on equity of 163.95%. As a group, sell-side analysts expect that Tonix Pharmaceuticals will post -18 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Tonix Pharmaceuticals in a research report on Friday. They set a “sell” rating for the company.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.